Paterson Institute for Cancer Research SCIENTIFIC REPORT 2005
Paterson Institute for Cancer Research SCIENTIFIC REPORT 2005
Paterson Institute for Cancer Research SCIENTIFIC REPORT 2005
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
J.L., van Zandwijk, N., Gridelli, C., van Meerbeeck,<br />
J.P., Crino, L., Brown, A., Fitzgerald, P., Aristides,<br />
M. and Schiller, J.H. (<strong>2005</strong>) Efficacy of gemcitabine<br />
plus platinum chemotherapy compared with other<br />
platinum containing regimens in advanced nonsmall-cell<br />
lung cancer: a meta-analysis of survival<br />
outcomes. Lung <strong>Cancer</strong>, 47, 69-80.<br />
Swaisland, H.C., Ranson, M., Smith, R.P.,<br />
Leadbetter, J., Laight, A., McKillop, D. and Wild,<br />
M.J. (<strong>2005</strong>) Pharmacokinetic drug interactions of<br />
gefitinib with rifampicin, itraconazole and metoprolol.<br />
Clin Pharmacokinet, 44, 1067-1081.<br />
Swaisland, H.C., Smith, R.P., Laight, A., Kerr, D.J.,<br />
Ranson, M., Wilder-Smith, C.H. and Duvauchelle,<br />
T. (<strong>2005</strong>) Single-dose clinical pharmacokinetic studies<br />
of gefitinib. Clin Pharmacokinet, 44, 1165-1177.<br />
Valle, J.W., Dangoor, A., Beech, J., Sherlock, D.J.,<br />
Lee, S.M., Scarffe, J.H., Swindell, R. and Ranson, M.<br />
(<strong>2005</strong>) Treatment of inoperable hepatocellular carcinoma<br />
with pegylated liposomal doxorubicin<br />
(PLD): results of a phase II study. Br J <strong>Cancer</strong>, 92,<br />
628-630.<br />
Ward, T.H., Danson, S., McGown, A.T., Ranson,<br />
M., Coe, N.A., Jayson, G.C., Cummings, J.,<br />
Hargreaves, R.H. and Butler, J. (<strong>2005</strong>) Preclinical<br />
evaluation of the pharmacodynamic properties of<br />
2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.<br />
Clin <strong>Cancer</strong> Res, 11, 2695-2701.<br />
Other publications<br />
Danson, S., Blackhall, F., Hulse, P. and Ranson, M.<br />
(<strong>2005</strong>) Interstitial lung disease in lung cancer: separating<br />
disease progression from treatment effects.<br />
Drug Saf, 28, 103-113.<br />
Ranson, M. and Jayson, G. (<strong>2005</strong>) Targeted antitumour<br />
therapy—future perspectives. Br J <strong>Cancer</strong>, 92<br />
Suppl 1, S28-31.<br />
____________________________________<br />
GENE THERAPY GROUP (page 24)<br />
Lez Fairbairn<br />
Refereed <strong>Research</strong> Papers<br />
Atkinson, D.E., Sibley, C.P., Fairbairn, L.J. and<br />
Greenwood, S.L. (<strong>2005</strong>) MDR1 P-gp expression<br />
and activity in intact human placental tissue; upregulation<br />
by retroviral transduction. Placenta, epub<br />
Aug 05.<br />
Green, K.L., Southgate, T.D., Mulryan, K.,<br />
Fairbairn, L.J., Stern, P.L. and Gaston, K. (<strong>2005</strong>)<br />
Diffusible VP22-E2 Protein Kills Bystander Cells<br />
and Offers a Route <strong>for</strong> Cervical <strong>Cancer</strong> Gene<br />
Therapy. Hum Gene Ther, epub Dec 05.<br />
Milsom, M.D., Duxbury, R., Gagen, D., Humphries,<br />
R.K., Schmidt, M., von-Kalle, C. and Fairbairn, L.J.<br />
(<strong>2005</strong>) Overexpression of HOXB4 confers a<br />
myelo-erythroid differentiation delay in vitro.<br />
Leukemia, 19, 148-153.<br />
Wool<strong>for</strong>d, L.B., Southgate, T.D., Margison, G.P.,<br />
Milsom, M.D. and Fairbairn, L.J. (<strong>2005</strong>) The P140K<br />
mutant of human O6-methylguanine-DNA-methyl transferase (MGMT) confers resistance in vitro and<br />
in vivo to temozolomide in combination with the<br />
novel MGMT inactivator O6-(4-bromothenyl)gua nine. J Gene Med, epub Aug 05, printed 2006, 8, 29-<br />
34.<br />
P A T E R S O N I N S T I T U T E S C I E N T I F I C R E P O R T 2 0 0 5<br />
59
Change language